The Challenge in Bioprocess Development: From Data to Knowledge - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Challenge in Bioprocess Development: From Data to Knowledge
The senior director of Oracle's Life Sciences Business Unit tackles some of the technical issues regarding regulatory standardization, software integration, and the trend toward visualization, among other things.


Pharmaceutical Technology


Looking ahead, by embedding the data-based process descriptors within monitoring and optimization algorithms, it will be viable to move toward processes that inherently adopt a quality by design (QbD) concept. The real challenge in using statistical tools to extract process descriptors is that in the development laboratory data are only available from a limited set of experiments. Statistical awareness in assessing the experimental results is crucial to guide the development program.

Production

In production, there is a need to ensure consistency of processes and provide tools that give an early warning of operational and process deviations to allow timely corrective action. The knowledge extraction philosophy for production is different from development. In production, the spread of data coverage is limited, and the objective is to look for occasional deviations from predominantly "consistent" behavior. In development, the spread of data is significantly larger, and the objective is to search for robust and effective design and operational areas. Consequently, the tools required for interpreting data into knowledge demand different capabilities, and the implementation of different fundamental algorithms is often a prerequisite. The knowledge extraction "toolbox" must, therefore, possess multiple capabilities.

The methods available for data analysis can address a significant proportion of industrial problems (2). A common strategy for data analysis is compression, the goal of which is twofold: first, to describe the variation in the data from a statistical data analysis perspective more effectively and, second, to enable the graphical representation of the data in the compressed data subspace, which allows the analyst to interrogate the data. The idea here is that patterns inherent within 1000 variables, for example, cannot be easily visualized individually, but using multivariate statistical projection-based techniques, the problem can be reduced to a limited number of variation indicators. This enables the visualization of the latent patterns. A multivariate statistical method that has been widely applied is principal component analysis. This technique has been extended to take account of both batch and nonlinear behavior. Other visualization strategies to support the compression methods include parallel coordinates plots (3).

There is a further challenge related to combining data from multiple sources logged at different frequencies. This raises data pretreatment issues that must be carefully addressed if original data features are not to be masked or lost. In the production environment, where consistency deviations are sought, these compression methods enable the interrogation and understanding of changes in the original process variables to address these challenges.

In the development environment, further analysis is required to understand the behavior of the process in the operating space. Data compression is the first step in data process model construction, which results in applying methods such as partial least squares. Variants are also required to capture both the batch and nonlinear behavior. These models of process behavior can then be used in knowledge-based experimental design strategies to design the most informative experiments.

Considering the solutions required, it might first be thought that "off-the-shelf" data analysis products can provide the answers. There are, however, many hurdles to overcome between identifying problems and implementing solutions. These range from data availability and configuration (which can typically take 33% of the time of the overall job) to tool identification, where the combined technical competencies in statistics, engineering, and biochemistry are necessary. There are also problems that require new fundamental data analysis approaches and, in particular, the area of process development is one where real benefits can be derived through their implementation. More efficient use of data and its appropriate analysis can help to reduce development times. Although this is an important business opportunity, the impact of small data sets raises further statistical challenges.

Extracting knowledge across products is one way of supplementing the limited information during early-stage development, but, again, data-analysis challenges are significant. One possible solution is combining data-based analysis with other information sources, which will result in hybrid information structures becoming important.

Conclusions

For most applications, the tools to deliver a solution are available, but there is a vast difference between having a set of tools and knowing how to use them effectively. The overall strategy adopted, and the selection of appropriate methods and decisions required to progress from recognizing a process problem to quickly and effectively attaining a solution only comes with experience. Those who believe that the purchase of a data-analysis package is the panacea to all problems need to be wary.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here